The Effect Of Nebulizied Nitroglycerin As An Adjuvant Therapy For Persistent Pulmonary Hypertension Of Newborns

Launched by ALEXANDRIA UNIVERSITY · Feb 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called nebulized nitroglycerin for infants with a serious condition known as Persistent Pulmonary Hypertension of the Newborn (PPHN). PPHN makes it hard for newborns to get enough oxygen because their blood vessels in the lungs are too tight. The researchers want to see how this treatment helps improve heart and lung function, as well as overall health indicators like oxygen levels and heart rate.

Eligible participants for this trial include infants who are 72 hours old or younger, born at least 37 weeks into pregnancy, and who still need a lot of oxygen support despite other treatments. Unfortunately, babies diagnosed with PPHN after 72 hours or those who have already tried other medications that didn’t work will not be included. For those who participate, they will receive nebulized nitroglycerin and will be closely monitored to see how their condition improves. This study is currently looking for participants, and it involves infants of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants ≤72 hours' old, ≥37 weeks of gestation, ≥50% FiO2 need despite lung recruitment, abnormal oxygen saturation index or echocardiographic signs of PPHN will be enrolled in the trial.
• Exclusion Criteria:
• • • Diagnosis of PPHN discovered after more than 72 hours.
• • Failure of used medications and need to administrate milrinone